FDA Committee to Review Novartis' Iron Overload Treatment Exjade

Drug Industry Daily
KEYWORDS Drug Approvals / NDA

The FDA’s Blood Products Advisory Committee will meet Sept. 29 to review Novartis’ new drug application (NDA) for Exjade, which could replace a much more difficult treatment for patients suffering chronic iron overload from blood transfusions.

To View This Article:


Subscribe To Drug Industry Daily